Literature DB >> 3883785

Cefotaxime treatment for women with community-acquired pelvic abscesses.

D L Hemsell, R Santos-Ramos, F G Cunningham, B J Nobles, P G Hemsell.   

Abstract

Forty-one women with pelvic abscesses complicating salpingitis were treated with parenteral cefotaxime, a newer cephalosporin. Abscesses ranged in size from 4 by 4 to 13 by 15 cm, and in 10 women (24%) they were greater than or equal to 10 cm. Neisseria gonorrhoeae was recovered from the endocervix in 17 women (41%). A mean of 26.7 gm of cefotaxime was given over a mean of 6.5 days, and operation was not required during initial therapy. Only two women (5%) required the addition of another antimicrobial. Chronic pelvic pain and recurrent infection were infrequent during the 31- to 43-month follow-up period. Five women (12%) were readmitted for elective surgical therapy because of persistent or recurrent adnexal mass 1 to 33 months following study entry. Six (15%) women became pregnant and were delivered of their infants a mean of 25 months following cefotaxime therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883785     DOI: 10.1016/0002-9378(85)90517-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.

Authors:  Yufei Lin; Henry R Kranzler; Lindsay A Farrer; Hongqin Xu; David C Henderson; Huiping Zhang
Journal:  Pharmacogenomics J       Date:  2020-02-07       Impact factor: 3.550

3.  Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin.

Authors:  D L Hemsell; G D Wendel; P G Hemsell; M L Heard; B J Nobles
Journal:  Infect Dis Obstet Gynecol       Date:  1993
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.